EQT

Avidicure is a biotechnology company developing a dual agonistic, multifunctional antibody modality engineered for targeted cancer immunotherapy. Its AVC-Boosters are designed to engage immune cells with high avidity and to localize activation within tumors, enabling potent anti-tumor activity as monotherapy while reducing off-target effects. The approach aims to advance oncology therapies by combining immune engagement with tumor-specific activation to support immune responses and potentially improve safety profiles.

Founded in 2018, Perfuze is a medical device company based in Galway, Ireland. It specializes in developing catheter-based aspiration technology designed to treat acute ischemic stroke efficiently and effectively.

Cornerstone Robotics develops medical robotic devices designed for precise surgical robotic systems. Their products feature multi-degree-of-freedom robotic arms, real-time imaging integration, and intuitive surgeon interfaces, enabling healthcare providers to perform advanced minimally invasive surgeries with greater control and consistency.

XyloCor Therapeutics, Inc. is a biopharmaceutical company specializing in the development of gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company focuses on innovative treatments aimed at addressing significant unmet medical needs. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, targeting individuals who have exhausted other treatment options. XyloCor's approach centers on stimulating the formation of new coronary blood vessels to enhance blood supply to areas of the heart that are inadequately perfused, thereby improving patient outcomes in those affected by heart failure and ischemic conditions. The company collaborates with Weill Cornell Medical College to advance its gene therapy technologies.

NUA Surgical is an award-winning company based in Galway, Ireland, developing and manufacturing surgical instruments for obstetrics and gynecology. Its patented disposable C-section retractor is designed to improve ergonomics and safety during caesarean deliveries, aiming to reduce complications and support safer care for mothers and infants.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

GeBBS Healthcare Solutions is a technology-enabled company that provides revenue cycle management (RCM) solutions to improve financial performance, compliance, and patient satisfaction. Founded in 2005 and headquartered in Culver City, California, GeBBS offers a range of services including Health Information Management (HIM), Revenue Cycle Management (RCM), Patient Access, Risk Adjustment Solutions, strategic outsourcing, and consulting services. The company serves hospitals, physician groups, health plans, and medical billing companies. With over 6,000 employees globally, GeBBS has formed strategic partnerships with various industry associations and organizations.

Asceneuron is a biotechnology company dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. It focuses on orphan tauopathies, Alzheimer's disease, and Parkinson's disease.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Perficient is an information technology consulting and software engineering firm that provides software development and digital consultancy services, IT strategy, and implementation support. The company helps clients leverage Internet-based technologies to improve productivity, competitiveness, and efficiency while strengthening relationships with customers, suppliers, and partners and reducing IT costs. Its offerings include big data analytics, technology platform deployments, enterprise content management, portals and collaboration, management consulting, custom applications, business integration, business process management, and customer relationship management. It serves the healthcare, financial services, retail, and electronics industries.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

Phagenesis develops a medical device for treating dysphagia, a swallowing disorder often resulting from stroke or brain injury. The device, Phagenyx, uses neurostimulation therapy to harness the brain's capacity for relearning lost functions via neuroplasticity. It consists of a base station and a catheter inserted through the nose, delivering optimal stimulations to the pharynx while recording patient data.

Onera Health, Inc. specializes in sleep diagnostic solutions and services aimed at identifying sleep disorders such as insomnia, sleep apnea, and narcolepsy. Founded in 2017 and headquartered in Palo Alto, California, with a research and development office in Eindhoven, the Netherlands, the company utilizes advanced sleep diagnostic patch systems that collect and analyze sleep data. These innovative solutions are designed to enhance patient care by providing comprehensive sleep test data to healthcare professionals across various settings, thereby improving the management of sleep-related ailments and potentially benefiting other medical fields through remote monitoring of chronic conditions. Onera Health's mission is to improve the health and quality of life for individuals struggling with sleep issues while also contributing to cost reductions in healthcare.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

LUMA Vision develops connected intravascular medical devices to support the treatment of cardiac arrhythmias. Using advanced four-dimensional imaging and artificial intelligence with real-time tissue analysis, the company enhances electrophysiology and structural heart interventions, aiming to improve patient outcomes, increase procedural safety, and reduce healthcare system costs.

Shinobi Therapeutics is a biotechnology company dedicated to developing innovative cell therapies that utilize hypoimmune CD8αβ induced pluripotent stem cells (iPS-T cells) to enhance cancer treatment and address other diseases. The company's advanced immune evasion technology aims to improve the effectiveness and accessibility of these therapies, ultimately reducing costs and enhancing patient outcomes. By focusing on durable responses and the potential for redosing, Shinobi Therapeutics strives to provide the healthcare industry with comprehensive immune therapies that can address a range of diseases, including cancer and genetic disorders.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

MinervaX is a biotechnology company focused on developing maternal vaccines to prevent infections caused by Group B streptococcus (GBS), which can lead to serious adverse pregnancy outcomes and life-threatening conditions for newborns. The company leverages a specific fusion protein that has shown promise in eliciting protective immunity against various clinically relevant GBS strains. By concentrating on this innovative vaccine approach, MinervaX aims to provide medical professionals with effective tools to safeguard newborns from bacterial infections, ultimately enhancing maternal and infant health outcomes.

AstronauTx focuses on restoring healthy function of astrocytes, a type of brain cell crucial for neuronal health and blood-brain barrier integrity. Its primary goal is to develop treatments targeting astrocyte dysfunction in dementias like Alzheimer's disease.

VetPartners empowers their people to perform through education, guidance, support, simple processes and respectful relationships. They foster and create connection across their own network and the wider industry they work in. They are committed to doing what is right, being empathetic and supportive.

Wellhub is a corporate wellness platform that connects employees with a network of partners to support fitness, physical health, mindfulness, nutrition, and sleep. The company helps firms create a healthy and engaged workforce by focusing on physical well-being and providing options that integrate wellness services into a single subscription. By promoting activity and healthy behaviors, Wellhub aims to drive lasting behavioral change, improve employee engagement and performance, and contribute to overall business success.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, focused on the development and manufacturing of therapeutic proteins aimed at restoring blood clotting in patients experiencing bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X that can promptly reinstate blood clotting in patients using direct factor Xa anticoagulants, such as rivaroxaban, apixaban, and edoxaban. These anticoagulants, commonly prescribed for the prevention and treatment of thrombosis and stroke, often lead to severe bleeding as a side effect. PseudoXa addresses this critical issue by effectively stopping and preventing bleeding, thereby enhancing the safety of anticoagulant therapy for millions of patients worldwide.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that develops and manufactures tissue-based medicines for inflammatory diseases. Incorporated in 2020, Evommune focuses on creating novel strategies to treat these disorders by addressing both symptoms and the underlying causes, thereby halting disease progression. The company employs a proprietary tissue-based platform that accelerates the discovery of innovative treatments, enhancing the potential for clinical success. With a commitment to improving the quality of life for patients, Evommune's pipeline includes initiatives aimed at tackling a range of prevalent inflammatory illnesses, positioning the company as a leader in advancing therapies in the fields of immunology and dermatology.

QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

EQT is a global private equity firm founded in 1994 that invests in mid-market companies through buyouts, expansion capital, growth equity, and infrastructure opportunities. It targets opportunities in Europe, North America, and Asia across sectors such as healthcare, life sciences, technology, industrials, consumer services, and real estate, seeking durable cash flows and meaningful intrinsic value. EQT pursues controlling or co-controlling stakes and collaborates with management to drive growth, improve operations, and expand internationally. The firm maintains a broad geographic footprint and an ownership orientation designed to build market-leading companies with sustainable competitive advantages. By combining sector expertise with disciplined capital allocation, EQT aims to create long-term value for its portfolio and stakeholders while adapting to evolving market dynamics.

Founded in 1989, SHL Medical specializes in designing, developing, and manufacturing advanced drug delivery systems. These include auto injectors, pen injectors, and inhalers for global pharmaceutical and biotechnology companies.

Developed, tested, and proven in Germany, Vara is a leading AI-powered breast cancer screening company on a mission to find every deadly breast cancer early. Vara’s Artificial Intelligence (AI) technology is embedded within the German Breast Cancer Screening Program and is backed by some of the most respected institutions in breast cancer screening in the world including Cambridge (UK), Memorial Sloan (US), and Karolinska (Sweden). Vara’s clinical evidence has also been published in Lancet Digital Health, demonstrating that Vara-assisted radiologists significantly outperform average radiologists and are able to find cancers that would otherwise have been missed. Vara works with healthcare stakeholders, radiology service providers, and medical doctor networks to improve access to high-quality screening in Germany, Egypt, India and Mexico.

eTheRNA Immunotherapies NV is a Belgium-based biotechnology company that specializes in the development of mRNA-based immunotherapies. Founded in 2013 and located in Niel, the company focuses on harnessing the immune system's dendritic cells to create treatments for melanoma, triple-negative breast cancer, and infectious diseases. eTheRNA has developed innovative TriMix technology that enhances the immune response, enabling patients to better combat these diseases. The company aims to be a leader in nucleic acid-based medicines, collaborating with partners to facilitate the creation of new drugs and improve patient outcomes. Additionally, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its mission.

FundamentalVR have been working with leading pharmaceutical companies to combine virtual and mixed reality with haptic feedback using their ‘FeelRealVR’ platform to create simulated surgical procedures to help educate and train healthcare professionals. The company works at the nexus of haptics, machine learning, and immersive technologies (XR). FundamentalVR was established in 2012 by Chris Scattergood in London, England.

Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.

Founded in 2015, ImCheck Therapeutics specializes in developing immunotherapeutics targeting members of the butyrophilin super-family for treating a range of autoimmune diseases, with a primary focus on immuno-oncology.

Ariceum Therapeutics is a clinical-stage radiopharmaceutical company that focuses on the detection and targeted treatment of aggressive cancers, particularly neuroendocrine tumors and other challenging malignancies. The company's lead product, 177Lu-satoreotide tetraxetan (Satoreotide), acts as an antagonist of the somatostatin type 2 receptor (SSTR2), which is commonly overexpressed in many neuroendocrine tumors. Ariceum is developing Satoreotide as a theranostic pair, which allows for both the diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, certain aggressive tumors, and childhood cancers. This approach aims to provide treatment options for conditions that currently have limited therapies and poor prognoses, enabling healthcare professionals to deliver more effective treatments with reduced side effects.

Envirotainer AB specializes in the production, development, and rental of active temperature-controlled containers designed for the air transportation of temperature-sensitive healthcare products. Established in 1986 and headquartered in Upplands Väsby, Sweden, the company has built a reputation as a global leader in secure cold chain solutions for the pharmaceutical industry. Envirotainer provides a range of services, including laboratory testing, qualification and validation support, data collection, and training through its Qualified Envirotainer Program. The company's extensive network includes operations centers in key locations such as Singapore, Dallas, Frankfurt, and Toronto, as well as a station in Hyderabad, India. By leveraging its innovative container solutions and global presence, Envirotainer meets the critical needs of pharmaceutical and biotech clients for reliable shipping solutions that maintain the integrity of temperature-sensitive products.

Founded in 2018, Perfuze is a medical device company based in Galway, Ireland. It specializes in developing catheter-based aspiration technology designed to treat acute ischemic stroke efficiently and effectively.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

AviadoBio focuses on developing transformative gene therapies for devastating neurodegenerative disorders such as frontotemporal dementia and amyotrophic lateral sclerosis. The company's platform combines proprietary technologies with a deep understanding of the brain to deliver effective treatments.

HotSpot Therapeutics is a biotechnology startup based in Boston, Massachusetts, established in 2017. The company specializes in the development of allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and utilizing data science, HotSpot Therapeutics employs a multidisciplinary approach to drug discovery. This approach aims to enhance the effectiveness of treatments and improve patient outcomes across a range of conditions.

Icon Group specializes in comprehensive cancer care services globally, offering medical and radiation oncology, hematology, health screening, pharmacy, chemotherapy, and compounding.

EQT is a global private equity firm founded in 1994 that invests in mid-market companies through buyouts, expansion capital, growth equity, and infrastructure opportunities. It targets opportunities in Europe, North America, and Asia across sectors such as healthcare, life sciences, technology, industrials, consumer services, and real estate, seeking durable cash flows and meaningful intrinsic value. EQT pursues controlling or co-controlling stakes and collaborates with management to drive growth, improve operations, and expand internationally. The firm maintains a broad geographic footprint and an ownership orientation designed to build market-leading companies with sustainable competitive advantages. By combining sector expertise with disciplined capital allocation, EQT aims to create long-term value for its portfolio and stakeholders while adapting to evolving market dynamics.

Founded in 2020, Egle Therapeutics is a biotechnology company based in Paris, France. It specializes in developing immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases.

LUMA Vision develops connected intravascular medical devices to support the treatment of cardiac arrhythmias. Using advanced four-dimensional imaging and artificial intelligence with real-time tissue analysis, the company enhances electrophysiology and structural heart interventions, aiming to improve patient outcomes, increase procedural safety, and reduce healthcare system costs.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that develops and manufactures tissue-based medicines for inflammatory diseases. Incorporated in 2020, Evommune focuses on creating novel strategies to treat these disorders by addressing both symptoms and the underlying causes, thereby halting disease progression. The company employs a proprietary tissue-based platform that accelerates the discovery of innovative treatments, enhancing the potential for clinical success. With a commitment to improving the quality of life for patients, Evommune's pipeline includes initiatives aimed at tackling a range of prevalent inflammatory illnesses, positioning the company as a leader in advancing therapies in the fields of immunology and dermatology.

Visus Therapeutics is a clinical-stage company developing innovative ophthalmic therapies to improve vision worldwide. Its primary focus is on creating eye drops for correcting presbyopia, with additional product candidates targeting ocular surface disease, glaucoma, and age-related macular degeneration.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Muna Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies aimed at slowing or halting devastating neurodegenerative diseases such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis.

Meine Radiologie Holding GmbH is a provider of radiological and radiotherapy treatment services focused on imaging diagnostics. The company specializes in offering radiology diagnostics and radiation treatments for both malignant and benign conditions. Additionally, it supports radiological and nuclear medicine practices by acting as a financial investor and professional management partner, particularly in succession planning. Through its services, Meine Radiologie Holding aims to create added value for doctors, employees, referrers, and patients by optimizing both central and local processes within the healthcare framework.

The blikk group is a growing network of radiological, nuclear medicine and nephrology practices using dialysis. As a reliable partner for patients and referring physicians, the practices of the association make a significant contribution to high-quality medical care. They all share the common claim to the highest quality and excellent education and training of medical and non-medical staff in all disciplines.

Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.

PAREXEL International Corporation is a biopharmaceutical services company that supports the pharmaceutical, biotechnology, and medical device industries globally. Founded in 1983 and headquartered in Waltham, Massachusetts, PAREXEL offers a wide range of services through three main segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics. The CRS segment specializes in managing clinical trials, including study design, patient enrollment, data management, and pharmacovigilance. The PCMS segment provides consulting services in drug development, regulatory affairs, and market access, assisting clients with product launch strategies and reimbursement issues. Additionally, the Perceptive segment offers technology solutions such as medical imaging, data management systems, and patient engagement applications. By delivering comprehensive expertise in clinical research and commercialization, PAREXEL facilitates scientific discoveries and the development of new treatments.

ManyPets is a pet insurance provider offering dog and cat insurance, comprehensive pet health plans, multi-pet coverage, and lifetime policies. The company delivers accessible pet health insurance and preventive wellness services through subscription-driven technology, providing pet owners with a personalized experience supported by human connections. It aims to improve outcomes for pets and their owners by combining flexible coverage with preventive care and easy-to-use digital tools.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Cerba HealthCare S.A.S. is a clinical pathology laboratory that offers a range of routine and specialized laboratory testing services. The company operates a network of medical laboratories that serve a diverse clientele, including private patients, physicians, hospitals, retirement and nursing homes, as well as pharmaceutical and biotech companies. Cerba HealthCare focuses on both standard laboratory tests and more complex specialty testing, enabling clients to interpret and analyze test results effectively. This comprehensive approach aids in the monitoring of patient health and provides significant insights based on clinical context, enhancing the decision-making process for healthcare providers.

XyloCor Therapeutics, Inc. is a biopharmaceutical company specializing in the development of gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company focuses on innovative treatments aimed at addressing significant unmet medical needs. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, targeting individuals who have exhausted other treatment options. XyloCor's approach centers on stimulating the formation of new coronary blood vessels to enhance blood supply to areas of the heart that are inadequately perfused, thereby improving patient outcomes in those affected by heart failure and ischemic conditions. The company collaborates with Weill Cornell Medical College to advance its gene therapy technologies.

Founded in 2015, Neurent Medical is a medical device company based in Galway, Ireland. It specializes in developing non-surgical treatments for chronic rhinitis using minimally invasive, hand-held radio-frequency devices.

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on researching and developing transformative therapies for cardio-metabolic diseases. Founded in 2019 and based in Naarden, the Netherlands, it is developing obicetrapib, an oral, low-dose CETP inhibitor intended to lower LDL-C and potentially address statin intolerance or residual risk in patients with ASCVD or familial hypercholesterolemia on maximally tolerated statin therapy. The company aims to improve patient care in populations where approved therapies are inadequate or poorly tolerated.

Sagility is a technology-enabled healthcare services company that provides business process management, analytics, and related services to clients in the U.S. healthcare and insurance sectors. It serves payers and providers, delivering core benefits administration functions such as claims management, enrollment, benefits plan design, premium billing, and credentialing, as well as data management and a range of clinical services including utilization management, care management, and population health management. The company also supports provider-focused needs through revenue cycle management, provider solutions, and payment integrity, along with case management and member engagement, all aimed at improving efficiency, costs, and outcomes.

Colisée is a prominent entity in the health care sector, specializing in the care and well-being of elderly individuals. The company operates over 90 retirement homes and nearly 70 home-based service agencies across France, Italy, and Spain. By focusing on both nursing home and home care services, Colisée provides essential daily care to residents and patients, as well as support for their families. With a workforce exceeding 6,700 employees, the organization is committed to delivering quality care tailored to the needs of the aging population.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, focused on the development and manufacturing of therapeutic proteins aimed at restoring blood clotting in patients experiencing bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X that can promptly reinstate blood clotting in patients using direct factor Xa anticoagulants, such as rivaroxaban, apixaban, and edoxaban. These anticoagulants, commonly prescribed for the prevention and treatment of thrombosis and stroke, often lead to severe bleeding as a side effect. PseudoXa addresses this critical issue by effectively stopping and preventing bleeding, thereby enhancing the safety of anticoagulant therapy for millions of patients worldwide.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

LUMA Vision develops connected intravascular medical devices to support the treatment of cardiac arrhythmias. Using advanced four-dimensional imaging and artificial intelligence with real-time tissue analysis, the company enhances electrophysiology and structural heart interventions, aiming to improve patient outcomes, increase procedural safety, and reduce healthcare system costs.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

FoRx Therapeutics is a biotechnology company focused on developing cancer therapies by targeting DNA replication stress. It seeks to drug key molecular targets involved in replication stress to create targeted anticancer drugs. Founded in 2019 and based in Basel, Switzerland, the company emphasizes a novel approach by targeting DNA replication stress pathways activated in cancer cells, with the goal of delivering first-in-class therapies that address the underlying mechanisms of tumor growth.

Schülke & Mayr GmbH, founded in 1889 and headquartered in Norderstedt, Germany, specializes in developing and manufacturing a wide range of hygiene and infection prevention products. The company's offerings include disinfectants, antiseptics, preservatives, biocides, medical skin care products, and active ingredients for deodorants and system cleaners. Schülke & Mayr provides tailored hygiene management solutions to combat hospital-acquired infections and supplies professional hygiene products for medical practices, outpatient surgery departments, and day clinics. Additionally, the company addresses industrial hygiene needs across various sectors, including food processing and the production of sterile medicinal products, along with offering preservatives for cosmetics and household products. Its global presence includes subsidiaries in several countries, enabling it to serve diverse industries such as healthcare, dental, food, pharmaceuticals, cosmetics, and metalworking. The company operates as a subsidiary of L'Air Liquide S.A.

Zayo specializes in providing bandwidth infrastructure services across diverse markets. It offers lit services and dark fiber products, supporting wireline and wireless customers, data centers, and government agencies with a robust network infrastructure. Additionally, Zayo provides carrier-neutral colocation facilities to enhance connectivity options.

A regional private healthcare provider operating in Singapore, Malaysia, and Indonesia. The company owns two tertiary hospitals in Malaysia, a healthcare training centre in Singapore, and maintains a network of representative offices across these countries.

Founded in 1989, SHL Medical specializes in designing, developing, and manufacturing advanced drug delivery systems. These include auto injectors, pen injectors, and inhalers for global pharmaceutical and biotechnology companies.

Founded in 2015, ImCheck Therapeutics specializes in developing immunotherapeutics targeting members of the butyrophilin super-family for treating a range of autoimmune diseases, with a primary focus on immuno-oncology.

Galderma is a global dermatology company founded in 1981 as a joint venture between Nestlé and L’Oréal. It later operated as Nestlé Skin Health before being carved out and launched as a standalone company in 2019, and it was listed on the SIX Swiss Exchange in March 2024. The company develops and markets science-based solutions across injectable aesthetics, dermatological skincare, and therapeutic dermatology, addressing conditions such as acne, rosacea, psoriasis and pigmentary disorders, skin cancer, and skin aging. Its products are sold in about 80 countries through a worldwide network of affiliates and distributors, supported by thousands of employees. The brand portfolio includes dermatology and aesthetic products such as Differin, Cetaphil, Restylane, Emervel, Mirvaso, Loceryl, and Metvix, among others.

iSTAR Medical specializes in developing ophthalmic implants made from biomaterials. Its flagship product is the STARflo glaucoma implant, a non-degradable, precision-pore device designed to reduce intraocular pressure in open angle glaucoma patients by enhancing natural fluid outflow. The company's products are sold through distributors worldwide and it operates from its eco-friendly R&D and manufacturing facility near Namur, Belgium.

Ellab is a manufacturer specializing in thermal validation and monitoring products, providing solutions that measure, record, and validate critical parameters in thermal processing. The company offers a diverse range of high-precision and modular systems, including wireless data loggers and thermocouple-based instruments, designed to support various applications such as sterilization, freeze-drying, environmental chambers, heat tunnels, and pasteurization. With a global presence, Ellab sells its products in over 65 countries, focusing on reducing the time-to-market and minimizing the risk of product loss for its clients.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Aldevron, LLC is a contract science organization based in Fargo, North Dakota, that specializes in the production of biological products, including plasmid DNA, proteins, antibodies, and nucleic acids. Founded in 1998, the company serves academic and research institutions, as well as pharmaceutical and biotechnology companies, by offering a range of services such as plasmid DNA production, protein production, antibody discovery, and mRNA production. Aldevron focuses on custom manufacturing and provides products for various applications, including gene therapy, gene editing, and diagnostics. Its offerings include DNA vaccine plasmids, reporter plasmids, retroviral vectors, and competent cell production, among others. The company also engages in GMP manufacturing and provides storage, distribution, and stability services, as well as gene synthesis and antibody processing. Aldevron operates both in the United States and Europe, facilitating vital discoveries in the life sciences sector.

Waystar is a healthcare technology company that offers a cloud-based platform to streamline and unify the healthcare revenue cycle. The platform covers the end-to-end process from pre-service engagement through post-service remittance and reconciliation, improving data integrity, reducing manual tasks, and speeding reimbursement and cash flow for healthcare providers. Its solution processes medical and patient payments, supports claims processing, and integrates with leading electronic health record and practice management systems. Waystar serves a broad network of providers, hospitals, health systems, and ambulatory services across the United States, helping organizations manage payments with greater efficiency and clarity. The company emphasizes platform-scale capabilities, collaboration with payer and provider ecosystems, and a focus on reducing costs and administrative burdens for customers and communities.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Imcyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, specializing in innovative immunotherapeutic solutions aimed at treating severe chronic autoimmune diseases. Founded in 2010, Imcyse is pioneering a unique technology platform that employs Imotopes™, specifically modified peptides that target immune cells responsible for organ damage. This approach facilitates the generation of cytolytic CD4 T-cells, which selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, thereby addressing diseases with limited treatment options. The company has shown proof of concept across various indications and has completed its initial clinical trial for type 1 diabetes, yielding promising outcomes. In addition to type 1 diabetes, Imcyse is actively developing a pipeline of therapies for multiple autoimmune diseases, aiming to provide effective treatment while preserving overall immune defense.

MHC Asia Group is a corporate managed healthcare provider based in Singapore, offering customized health plans, third-party administration services, and wellness programs. With over 1,200 clinical touchpoints, MHC serves approximately 800,000 employees across various sectors. They leverage proprietary technology to deliver sustainable outcomes and have achieved significant cost savings in chronic management programs.

WS Audiology A/S is a manufacturer and distributor of hearing instruments and audiological solutions, headquartered in Lynge, Denmark. Established in 2019 through a partnership between Sivantos and Widex, the company aims to enhance hearing care for individuals with hearing needs. Its product offerings include a comprehensive range of hearing aids, such as receiver-in-the-ear devices, assistive listening devices, and solutions for single-sided deafness. Additionally, WS Audiology provides accessories like hearing aid batteries, remote controls, and electronic drying stations. The company's diverse product spectrum caters to various price categories, ensuring that those with hearing loss have access to effective solutions for improved hearing and understanding.

Atlantic Therapeutics Limited is a medical technology company based in Galway, Ireland, with additional offices in London, Paris, and Salem. Established in 2013, the company specializes in the manufacture and distribution of medical devices designed for pelvic floor muscle strengthening and nerve stimulation. Its key products include Innovotherapy, a device aimed at enhancing pelvic floor muscle function, and INNOVO, a wearable device specifically targeting stress urinary incontinence by addressing its underlying causes. Atlantic Therapeutics distributes its products through a network of distributors across Ireland, the United Kingdom, France, Germany, and the Middle East. The company operates as a subsidiary of Bio-Medical Research Limited.

Karo Pharma is a pharmaceutical company. The company develops and markets products for pharmacies and directly to the healthcare sector. The product portfolio includes over-the-counter and prescription pharmaceuticals as well as medical devices.

XyloCor Therapeutics, Inc. is a biopharmaceutical company specializing in the development of gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company focuses on innovative treatments aimed at addressing significant unmet medical needs. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, targeting individuals who have exhausted other treatment options. XyloCor's approach centers on stimulating the formation of new coronary blood vessels to enhance blood supply to areas of the heart that are inadequately perfused, thereby improving patient outcomes in those affected by heart failure and ischemic conditions. The company collaborates with Weill Cornell Medical College to advance its gene therapy technologies.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

Endotronix develops and manufactures implantable wireless pulmonary artery pressure sensors for early detection of worsening heart failure. The company's platform includes a cloud-based disease management data system, enabling remote patient monitoring.

HyTest Ltd. is a manufacturer of monoclonal antibodies and antigens specifically for the diagnostic industry, founded in 1994 and headquartered in Turku, Finland. The company specializes in developing innovative solutions for assay development and research applications, providing a range of products and services that include antibodies, antigens, and various biomarkers. HyTest's offerings are utilized across multiple clinical areas, such as cardiac markers, infectious diseases, metabolic syndrome, and veterinary diagnostics. By focusing on research and development, HyTest enables its clients to deliver accurate testing solutions in the in vitro diagnostic sector.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

SUSE is a global leader in open source solutions, providing reliable and enterprise-grade software to a diverse range of industries, including automotive, telecom, banking, healthcare, manufacturing, retail, and technology. With a strong focus on Enterprise Linux, Kubernetes Management, and Edge solutions, SUSE supports mission-critical workloads for over 60% of the Fortune 500 companies. The company emphasizes collaboration with partners and communities to empower customers to innovate across various environments, from data centers to the cloud and edge. SUSE offers consulting, blended services, and training and certification, primarily generating revenue from subscriptions. Headquartered in Nuremberg, Germany, SUSE employs nearly 2,000 people globally and derives a significant portion of its revenue from North America.

MediFox GmbH, founded in 1994 and headquartered in Hildesheim, Niedersachsen, Germany, specializes in developing software solutions for ambulatory nursing care service providers and nursing care homes. The company offers enterprise system software designed to support outpatient care services, inpatient facilities, and therapeutic practices. MediFox's software encompasses essential services such as resource and route planning, care and support documentation, management information systems, and administration services, including billing and factoring. By providing these tools, MediFox enables care providers to enhance their organizational structure and streamline their processes in response to evolving industry needs.

Segra is one of the largest independent fiber bandwidth infrastructure companies in the United States, specializing in fiber-based network services primarily for the healthcare and education sectors. The company provides high-speed broadband internet, digital television, digital telephone, and managed Wi-Fi services. These offerings are designed to enhance productivity for businesses, backed by local and professional customer support. Through its comprehensive suite of services, Segra aims to meet the connectivity needs of its clients while fostering growth and efficiency in their operations.

Simplify Medical, Inc. is a medical device company specializing in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs intended for spinal use. Founded in 2013 and based in Sunnyvale, California, it offers innovative products such as the Simplify Disc, a non-metallic, MRI-compatible artificial cervical disc that preserves motion while allowing for full diagnostic imaging without the need for traditional CT scans. This technology minimizes patient exposure to ionizing radiation and is tailored for skeletally mature patients undergoing reconstruction at one level from C3 to C7 following discectomy procedures. Simplify Medical markets its products through distributors in the United Kingdom, Germany, and other international markets. The company was previously known as Simplify Delaware, Inc. before rebranding in February 2015.

Aelin Therapeutics is a privately held Belgian biotherapeutics company founded in 2017, based in Heverlee. The company develops antibiotics and therapeutics using its proprietary Pept-in technology, which leverages protein aggregation to induce functional knockdown of target proteins. This approach allows for the rational design of novel biotherapeutics that can address undruggable human targets and combat resistant bacteria like Methicillin-resistant Staphylococcus aureus (MRSA). Aelin Therapeutics' platform offers a unique mode of action and intracellular target space, differentiating it from traditional small molecule drugs or protein-based therapeutics. The company's technology has shown applications in various areas including bacteria, cancer cells, fungi, viruses, and plant cells, with supporting preclinical Proof of Concept data published in high-impact journals such as Science.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Clinical Innovations is the largest manufacturer of labor and delivery medical devices, leading several product categories worldwide. Founded in 1993, the company has grown its global footprint while investing in research and development of cutting‑edge technologies. Its flagship products include the Koala Intrauterine Pressure Catheter and the Kiwi Vacuum‑Assisted Delivery System, both designed to improve outcomes for mothers and newborns. With a seasoned management team and ISO13485 certification, Clinical Innovations emphasizes quality, customer service, and rapid response to market trends. The firm maintains strong relationships with major medical distributors and operates as a subsidiary of the Prizker Group.